PR1 peptide (derived from Neutrophil elastase and Proteinase 3) (PR1)

PR1 is a nonameric peptide with the sequence VLQELNVTV, derived from the azurophilic granule proteins neutrophil elastase (NE) and proteinase 3 (PR3) (Molldrem et al., Nature Medicine, 2000). It is a well-characterized leukemia-associated antigen (LAA) that is presented on the cell surface by the human leukocyte antigen HLA-A*0201 (Alatrash et al., Expert Review of Hematology, 2012). While NE and PR3 are expressed in normal myeloid cells, they are significantly overexpressed in malignant myeloid cells, including those found in acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and myelodysplastic syndrome (MDS) (Molldrem et al., Blood, 1996). This differential expression allows PR1 to serve as a target for various immunotherapeutic approaches, such as peptide vaccines, T-cell receptor (TCR)-like antibodies like h8F4, and adoptive T-cell transfers (Sergeeva et al., Blood, 2011). Clinical studies have demonstrated that PR1-specific cytotoxic T lymphocytes (CTLs) can selectively eliminate leukemic cells while sparing normal hematopoietic stem cells, although transient neutropenia remains a potential safety concern due to the presence of the target proteins in mature neutrophils (Molldrem et al., Blood, 2003).

Other names

PR1 peptideNeutrophil elastase-derived peptide PR1Proteinase 3-derived peptide PR1VLQELNVTV peptidePR1-HLA-A*0201 complex

Induction of T-cell mediated cytotoxicity against malignant cells presenting the PR1 peptide in the context of HLA-A*0201.